Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC-5: Durvalumab Consolidation in Unresectable Stage III NSCLC
NCT03706690Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 10
01
Overview
A Phase 3 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Nov 2018; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03706690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03706690.